Abstract 672P
Background
CDK8 and its paralog CDK19 are part of the mediator complex connecting enhancers and core promoters and regulating genes responsible for oncogenic transformation and differentiation. RVU120 is a selective CDK8/19 inhibitor, currently in phase 1 clinical development. RVU120 showed strong anticancer activity in non-clinical cancer models.
Methods
In the ongoing phase I/II study (NCT05052255), patients with metastatic or locally advanced solid tumors receive RVU120 until disease progression or unacceptable toxicity. Primary objectives are safety, tolerability, and determination of the recommended phase 2 dose. Secondary objectives include ORR, pharmacokinetic and pharmacodynamics. Molecular response to RVU120 is assessed by genetic profiling of tumor biopsies and ctDNA. NanoString technology is used for transcriptional profiling of tumor biopsies.
Results
As of 01 May 2023, there were 30 patients treated across 7 cohorts (75 - 375 mg). The most frequent AEs were nausea and vomiting, all were G1 or 2. No patient experienced a DLT, 10 SAEs were reported in 6 patients (worsening of tumoral pain, urinary tract infection, medullary compression, lower GI bleeding, worsening of basal ataxia/dizziness, renal calculi, stroke). One patient died following an SAE of general physical health deterioration due to PD. No SAE was considered IMP related. A total of 15 patients had at least 1 RECIST assessment: 2 PD (21% and 26% increase in TL size), 13 radiologic SD (between -4% and +11% change in TL size). Out of these, a patient with refractory pancreatic cancer achieved a reduction of CA19.9 on 3 consecutive time points and radiologic SD after cycle 3. Pharmacodynamic profiling of all patients revealed target engagement of >70% at doses up to 375 mg. Data from genetic and transcriptomic profiling will be presented.
Conclusions
After 7 dose levels with single agent RVU120 (up to 375 mg), a favorable safety profile was observed. Most TEAEs were mild/moderate, no DLTs nor IMP related SAEs were reported. RECIST assessments of 15 patients demonstrated radiologic SD in 13 patients. Dose escalation is currently ongoing with PK modeling indicating high target engagement.
Clinical trial identification
NCT05052255.
Editorial acknowledgement
Legal entity responsible for the study
Ryvu Therapeutics SA.
Funding
Ryvu Therapeutics SA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
690P - Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I/II study
Presenter: Manish R Patel
Session: Poster session 17
691P - Efficacy of ABBV-400 monotherapy in patients with MET gene amplified advanced solid tumors
Presenter: John Strickler
Session: Poster session 17
692P - First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors
Presenter: Wen wee Ma
Session: Poster session 17
693P - Preclinical activity of HLX43, a PD-L1-targeting ADC, in multiple PD-1/PD-L1 refractory/resistant models
Presenter: Yongqiang Shan
Session: Poster session 17
694P - Full efficacy analysis of phase I/II trial investigating bexmarilimab, a novel macrophage-guided immunotherapy in refractory solid tumors
Presenter: Petri Bono
Session: Poster session 17
695P - A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma
Presenter: Elena Garralda
Session: Poster session 17
696P - SIM1811-03 (SIM0235), an anti-tumor necrosis factor receptor-2 (TNFR2) monoclonal antibody, in patients with advanced solid tumor and/or cutaneous T cell lymphomas (CTCL): Preliminary results from an on-going first-in-human phase I trial in China
Presenter: Furong Liu
Session: Poster session 17
699P - Immunogenicity and reactogenicity of BNT162b2 COVID-19 mRNA vaccine in long-survivor (LS) patients with metastatic lung cancer (mLC) after primary immunization (PV) and booster (BD): COVALENCE study
Presenter: Emanuele Vita
Session: Poster session 17